Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

2010 • 2,043 citations

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

2011 • 1,810 citations

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

2010 • 1,732 citations

Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

2008 • 1,579 citations

Ras oncogenes: split personalities

2008 • 1,405 citations

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

2010 • 971 citations

Ras in Cancer and Developmental Diseases

2011 • 841 citations

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

2011 • 745 citations

TP53Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck

2007 • 732 citations

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

2010 • 724 citations

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer

2010 • 562 citations

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials

2012 • 549 citations

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

2009 • 543 citations

Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.

2002 • 408 citations

Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer

2011 • 344 citations

Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer

2010 • 274 citations

The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients

2010 • 256 citations

Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

2013 • 232 citations

Recurrent KRAS codon 146 mutations in human colorectal cancer

2006 • 229 citations

Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab

2012 • 229 citations

Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer

2009 • 223 citations

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients

2008 • 161 citations

Metastatic colorectal cancer

2001 • 130 citations

BRAF Mutation Status and Survival after Colorectal Cancer Diagnosis According to Patient and Tumor Characteristics

2012 • 121 citations

Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study

2012 • 88 citations

KRAS mutation profile in colorectal carcinoma and novel mutation--internal tandem duplication in KRAS.

2008 • 31 citations

Surveyor^TM nuclease-based detection of p53 gene mutations in haematological malignancy

2007 • 30 citations

Cited By (0)

No citing papers found in database